Amgen Inc - Sep 19, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: 10%+ Owner
Signature: /s/ Peter H. Griffith, Executive Vice President and Chief Financial Officer
Stock symbol: NMRA
Transactions as of: Sep 19, 2023
Transactions value $: $29,999,985
Form type: 4
Date filed: 9/19/2023, 07:52 PM
Previous filing: Sep 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NMRA	Common Stock	Conversion of derivative security		+33.6M			33.6M	Sep 19, 2023	Direct	F1
transaction	NMRA	Common Stock	Purchase	$30M	+1.76M	+5.25%	$17.00^*	35.4M	Sep 19, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NMRA	Series A-2 Preferred Stock	Conversion of derivative security		-32.8M	-100%		0	Sep 19, 2023	Common Stock	32.8M		Direct	F1
transaction	NMRA	Series B Preferred Stock	Conversion of derivative security		-850K	-100%		0	Sep 19, 2023	Common Stock	850K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.